|
1) Elliot WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet. 2007; 369: 201-7
|
|
|
|
2) Abuissa H, Jones PG, Marso SP, et al. Angio-tensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trials. J Am Coll Cardiol. 2005; 46: 821-6
|
|
|
|
|
|
3) ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treat-ment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002; 288: 2981-97
|
|
|
|
|
|
4) Yusuf S, Gerstein H, Hoogwerf B, et al. Ramipril and the development of diabetes. JAMA. 2001; 286: 1882-5
|
|
|
|
|
|
5) Kjeldsen SE, Julius S, Mancia G, et al. Effects of valsartan compared to amlodipine on preven-ting type 2 diabetes in high-risk hypertensive patients: the VALUE trial. J Hypertens. 2006; 24: 1405-12
|
|
|
|
|
|
6) CASE-J trial group. Effects of candesartan compared with amlodipine in hypertensive pa-tients with high cardiovascular risks: candesartan antihypertensive survival evaluation in Japan trial. Hypertension. 2008; 51: 393-8
|
|
|
|
|
|
7) Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol, Lancet. 2002; 359: 995-1003
|
|
|
|
|
|
8) Hansson L, Lindholm LH, Niskanen L, et al. Effect of angiotensin converting enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet. 1999; 353: 611-6
|
|
|
|
|
|
9) The TRANSCEND Investigators. Effects of telmisartan on glucose levels in people at high risk for cardiovascular disease but free from diabetes. Diabetes Care. 2011; 34: 1902-7
|
|
|
|
|
|
10) NAVIGATOR Study Group. Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med. 2010; 362: 1477-90
|
|
|
|
|
|
11) The DREAM Trial Investigators. Effect of ramipril on the incidence of diabetes. N Engl J Med. 2006; 355: 1551-62
|
|
|
|
|
|
12) Hansson L, Lindholm LH, Ekbom T, et al. Randomised trial of old and new antihypertenive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension 2 study. Lancet. 1999; 354: 1751-6
|
|
|
|
|
|
13) Second Australian National Blood Pressure Study Group. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med. 2003; 348: 583-92
|
|
|
|
|
|
14) SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind inter-vention trial. J Hypertens. 2003; 21: 875–86
|
|
|
|
|
|
15) VALUE Trial Group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004; 363: 2022-31
|
|
|
|
|
|
16) Jikei Heart Study Group. Valsartan in a Japanese population with hypertension and other cardio-vascular disease (Jikei Heart Study): a randomi-sed, open-label, blinded endpoint morbidity- mortality study. Lancet. 2007; 369: 1431-9
|
|
|
|
|
|
17) KYOTO HEART Study Group. Effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high cardiovascular risks: KYOTO HEART Study. Eur Heart J. 2009; 30: 2461-9
|
|
|
|
|
|
18) Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009; 338: b1665
|
|
|
|
|
|
19) HOPE Study Investigators. Effects of an angio-tensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000; 342: 145-53
|
|
|
|
|
|
20) European trial on reduction of cardiac events with perindopril in stable coronary artery disease investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet. 2003; 362: 782-8
|
|
|
|
|
|
21) The PEACE Trial Investigators. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med. 2004; 351: 2058-68
|
|
|
|
|
|
22) CAMELOT Investigators. Effect of antihyper-tensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA. 2004; 292: 2217-25
|
|
|
|
|
|
23) Svensson P, de Faire U, Sleight P, et al. Compa-rative effects of ramipril on ambulatory and office blood pressures. A HOPE substudy. Hypertension. 2001; 38: e28-32
|
|
|
|
|
|
24) CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet. 2003; 362: 767-71
|
|
|
|
|
|
25) Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001; 345: 1667-75
|
|
|
|
|
|
26) Valsartan in Acute Myocardial Infarction Trial (VALIANT) Investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003; 349: 1893-906
|
|
|
|
|
|
27) HEAAL Investigators. Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. Lancet. 2009; 374: 1840-8
|
|
|
|
|
|
28) Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999; 341: 709-17
|
|
|
|
|
|
29) Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003; 348: 1309-21
|
|
|
|
|
|
30) Eklind-Cervenka M, Benson L, Dahlström U, et al. Association of candesartan vs losartan with all-cause mortality in patients with heart failure. JAMA. 2011; 305: 175-82
|
|
|
|
|
|
31) EMPHASIS-HF Study Group. Eplerenone in patients with systolic heart filure and mild symptoms. N Engl J Med. 2010; 364: 11-21
|
|
|
|
|
|
32) Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med. 2004; 351: 543-51
|
|
|
|
|